Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16579840 | 0.86 | TDP1 (0.30) | TDP1 | |
| SCHEMBL11668547 | 0.84 | — | — | |
| SCHEMBL25842821 | 0.82 | TDP1 (0.36) | TDP1DGAT1CYP2D6HDAC3HDAC1 | |
| SCHEMBL16744314 | 0.81 | DGAT1 (0.33) | TDP1DGAT1CYP2D6HDAC3HDAC1 | |
| SCHEMBL1951896 | 0.79 | KDM4E (0.52) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL5856578 | 0.79 | TDP1 (0.46) | TDP1DGAT1CYP2D6 | |
| SCHEMBL16313462 | 0.79 | CYP2D6 (0.33) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL20069102 | 0.79 | CYP2D6 (0.33) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL7256439 | 0.78 | TSHR (0.43) | CA12CA2CA14 | |
| SCHEMBL1540854 | 0.77 | TDP1 (0.32) | TDP1DGAT1CYP2D6HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | ACTIO BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | ACTIO BIOSCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| CN-116283647-A | Prodrug modulators that integrate stress pathways | 卡里科生命科学有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-113423685-B | Prodrug modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-113423685-A | Prodrug modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-09-21 | — | — | CN | disclosed |
| EP-3864003-A1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | KCNT1, KCNT2, KCNN3 | TDP1 3206/4885DGAT1 251/4885CYP2D6 758/4885 |
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | KCNT1, KCNT2, KCNJ2 | TDP1 4595/4885DGAT1 252/4885CYP2D6 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.